Concurrent pleural and pericardial effusions in advanced lung adenocarcinoma
, 1, 1, 1, 1
Abstract
Lung adenocarcinoma is a common malignancy that often spreads to different organs, such as the pleura and pericardium. The concurrent presence of pleural and pericardial effusions often signifies an advanced stage of the disease. This case report delineates the presentation of a 71-year-old male diagnosed with advanced lung adenocarcinoma complicated by concurrent pleural and pericardial effusions. Diagnostic imaging and cytological analysis confirmed the diagnosis, guiding subsequent treatment. Pericardiocentesis and thoracentesis were initiated to alleviate symptoms and improve quality of life. The case underscores the complexities involved in managing advanced lung adenocarcinoma accompanied by pleural and pericardial involvement.
Keywords: pleural effusionpericardial effusionadenocarcinoma of lung
References
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1): 7–33.
- Ben-Horin S, Bank I, Guetta V, et al. Large symptomatic pericardial effusion as the presentation of unrecognized cancer: a study in 173 consecutive patients undergoing pericardiocentesis. Medicine (Baltimore). 2006; 85(1): 49–53.
- Detterbeck FC, Marom EM, Arenberg DA, et al. The IASLC lung cancer staging project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016; 11(5): 666–680.
- Travis WD, Brambilla E, Nicholson AG, et al. WHO Panel. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015; 10(9): 1243–1260.
- Karpathiou G, Stefanou D, Froudarakis ME. Pleural neoplastic pathology. Respir Med. 2015; 109(8): 931–943.
- Saab J, Hoda RS, Narula N, et al. Diagnostic yield of cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419 specimens. Cancer Cytopathol. 2017; 125(2): 128–137.
- Froudarakis ME. Diagnostic work-up of pleural effusions. Respiration. 2008; 75(1): 4–13.
- Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4): 366–377.
- Kato R, Hayashi H, Chiba Y, et al. Prognostic impact of minimal pericardial effusion in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2017; 18(6): e449–e455.
- Niho S, Kubota K, Yoh K, et al. Clinical outcome of small cell lung cancer with pericardial effusion but without distant metastasis. J Thorac Oncol. 2011; 6(4): 796–800.
- Cullinane CA, Paz IB, Smith D, et al. Prognostic factors in the surgical management of pericardial effusion in the patient with concurrent malignancy. Chest. 2004; 125(4): 1328–1334.
- Çelik S, Lestuzzi C, Cervesato E, et al. Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions. J Thorac Cardiovasc Surg. 2014; 148(5): 2288–2293.
- Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023. J Natl Compr Canc Netw. 2023; 21(4): 340–350.
- Tamiya A, Tamiya M, Shiroyama T, et al. Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Ann Oncol. 2013; 24(4): 980–985.
- Ritzwoller DP, Carroll NM, Delate T, et al. Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network. Lung Cancer. 2012; 78(3): 245–252.
